Pharmaceutical Contract Manufacturing Marketplace - Market Research

Pharmaceutical Contract Manufacturing Marketplace, The

Product Type: Market Report
Published Date: January 2002
Published By: Kalorama Information
Page Count: 158
Order Code: R566-0036
Print Copy $3500
Outsourcing pharmaceutical production is not new, and the benefits to big pharma companies are well documented. However, rapid changes in the kinds of drugs, the delivery technologies they will require, the expertise to scale-up new biopharmaceuticals, and even changes in capacity demand are all on the horizon for the contract manufacturing marketplace. One thing is for certain, contract manufacturing organizations (CMOs) will need to adapt to the changing needs of the pharma industry in the new age of drug discovery.
This research study on the status and outlook for pharmaceutical outsourcing is looking into such pressing issues as:
current and future capacity and demand
delivery and production technologies that CMOs will need to master
the state of "manufacturing R&D"?the research into effective scale-up
the demands of government and industry partners in the QC realm
the effects of industry trends, such as consolidation and specialization
Kalorama has conducted scores of interviews with executives and engineers at pharmaceutical companies and at CMOs to validate projections and to assess expectations and on both sides of this large and important marketplace.
Scope and Methodology
This report analyzes the state of the manufacturing segment of the pharmaceutical outsourcing business, reporting figures on the three key markets of North America, Europe, and Japan. The report profiles several companies involved in marketing their manufacturing services to the pharmaceutical companies, including Quintiles, Cammbrex, Genzyme, and others. The report generally reviews the nature and direction of where the pharmaceutical contract industry, specifically contract manufacturing, is headed and the challenges it faces. Discussions of contract research work, while not the focus of this report, are included in some areas because they represent a more mature model of outsourcing in the pharmaceutical industry as a whole and can be instructive.
Market forecasts are based on an examination of current market conditions and on investigations into the development of new products by key suppliers. This information also is weighted with projected timing and the probability of receiving FDA approval to market products. The information is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, multiple interviews were conducted with key company executives and industry analysts. Research was conducted from June 2001 to November 2001.